Pancreatic Atrophy Management

Introduction to Pancreatic Enzyme Replacement Therapy (PERT)

The American Gastroenterological Association recommends starting pancreatic enzyme replacement therapy (PERT) with 40,000 USP units of lipase during each meal and 20,000 units with snacks in adults, to prevent long-term malnutrition, sarcopenia, and metabolic bone disease 1, 2
PERT must be taken during the meal, not before or after, to maximize mixing with food and optimize nutrient digestion 1
Dose adjustments should be based on meal size and fat content—larger, fattier meals require higher doses 1
If symptoms persist, double the dose and consider adding a proton pump inhibitor or H2 receptor antagonist to prevent acid-mediated enzyme inactivation 1, 3

Patients should consume a well-balanced diet with normal fat content (approximately 30% of total energy intake), not a low-fat diet 5
Fat restriction is only necessary if steatorrhea persists despite adequate PERT and exclusion of bacterial overgrowth 6, 5
Protein intake should be 1.0-1.5 g/kg body weight daily 6, 5
Distribute food across 5-6 small meals per day rather than 3 large meals 6, 5
Avoid very high-fiber diets as they increase flatulence, fecal weight, and fat losses 5

Fat-soluble vitamin deficiencies (A, D, E, K) are universal in pancreatic atrophy and must be systematically addressed 1, 3, 4
Screen for vitamins A, D, E, and K at baseline and at least every 12 months 3, 5
Also monitor B12, folate, thiamine, selenium, zinc, and magnesium annually 1, 3
Check hemoglobin A1c regularly to screen for diabetes 1, 3
Vitamin D deficiency occurs in 58-78% of patients—supplement with 38 μg (1,520 IU) daily orally or 15,000 μg (600,000 IU) intramuscularly 5
Vitamins D and K are particularly critical as they prevent osteopathy and reduce fracture rates 1, 3

Obtain a baseline DEXA scan and repeat every 1-2 years, as metabolic bone disease is extremely common in pancreatic atrophy 1, 2, 3
Pancreatic atrophy leads to chronic low-grade inflammation and a catabolic state that accelerates bone loss 1, 2
Treatment with vitamins D and K reduces fracture rates 1, 3

Effective treatment is defined by reduction in steatorrhea and gastrointestinal symptoms, weight gain and increased muscle mass, improved muscle function, and normalization of fat-soluble vitamin levels 1, 3, 5
Comprehensive assessment includes anthropometric measures, serum biomarkers, clinical assessment, and consideration of psoas muscle size at L3 level on CT imaging 1, 2, 3, 4, 5
Stable patients should be assessed at least annually, with more frequent monitoring needed when initiating treatment or if the patient's condition is changing 1
Annual updates of fat-soluble vitamins and nutritional markers are reasonable in stable patients 1, 2, 3

Alcohol cessation and smoking cessation are mandatory—continued use worsens outcomes and accelerates disease progression 6
Analgesics should be taken before meals to reduce postprandial pain and increase food intake 6

Approximately 40-90% of patients with severe pancreatic insufficiency develop glucose intolerance, and 20-30% develop overt diabetes 6
Glucagon secretion is also impaired, increasing hypoglycemia risk during insulin treatment 6
This requires careful glucose monitoring and diabetes management 1, 3
The adequate implementation of PERT improves quality of life and ultimately reduces patient mortality and morbidity 2, 3